Related Experiment Video

Updated: Jun 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Screening of potential molecular targets for colorectal cancer therapy

Kimi Honma1, Ichiro Takemasa, Ryo Matoba

  • 1Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan;

International Journal of General Medicine
|April 3, 2010
PubMed

Insights

Researchers identified proteasome subunit, alpha-type, 7 (PSMA7) and ras-related nuclear protein (RAN) as key targets for colorectal cancer therapy. Silencing these genes effectively induced cancer cell death, offering potential for new treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) is a significant global health concern and a leading cause of cancer mortality.
  • Identifying novel molecular targets is crucial for developing effective CRC therapies.
  • Gene expression profiling reveals elevated levels of specific genes in CRC tissues.

Purpose of the Study:

  • To screen small interfering RNAs (siRNAs) targeting 97 overexpressed genes in colorectal cancer.
  • To evaluate the potential of these siRNAs in inducing apoptosis in human colorectal cancer cells (HT-29).
  • To identify novel molecular targets for colorectal cancer treatment.

Main Methods:

  • Utilized HT-29 human colorectal cancer cells for in vitro screening.
  • Tested siRNAs against 97 genes upregulated in colorectal cancer.
  • Assessed apoptosis induction upon gene silencing.
  • Validated gene expression in normal colon and tumor tissues.
  • Performed in vivo studies using HT-29 xenograft mouse models.

Main Results:

  • Downregulation of proteasome subunit, alpha-type, 7 (PSMA7) and ras-related nuclear protein (RAN) most effectively induced apoptosis in HT-29 cells.
  • PSMA7 and RAN exhibited high expression in colorectal cancer cell lines and tissues, including other tumor types, compared to normal tissues.
  • In vivo administration of PSMA7 and RAN siRNAs significantly promoted apoptosis in HT-29 xenograft tumors.

Conclusions:

  • Silencing PSMA7 and RAN induces apoptosis in colorectal cancer cells.
  • PSMA7 and RAN represent promising molecular targets for developing novel colorectal cancer therapeutics.
  • RNA interference-based strategies targeting PSMA7 and RAN warrant further investigation for clinical application.
Keywords:
PSMA7RANRNAicolorectal cancermolecular target

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...